With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Subscribe To Our Newsletter & Stay Updated
